Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

LGC licenses Orchid to test for drug metabolising gene

10.06.2002


LGC, the UK`s leading independent provider of genetic testing services, has issued its first testing licence for the key DNA variant in the drug metabolising gene CYP2D6 to Orchid BioSciences Inc. LGC holds the exclusive commercialisation rights to the patented diagnosis of this `poor metaboliser` gene variation and, in granting this first licence, will make access to this beneficial technology available to leading companies internationally for the first time.



The gene CYP2D6 controls an enzyme in the human liver. About 6% of the Caucasian population have a genetically pre-determined deficiency in this enzyme. This means that they do not metabolise about 20% of currently prescribed medications correctly. The genetic variation in the gene CYP2D6, known as *4, was first invented by Imperial Cancer Research Fund (ICRF) scientists and patented by the Fund in the early 1990s. One of the inventors, Professor Roland Wolf, joined the University of Dundee and ICRF granted the University an exclusive licence. Subsequently, the University granted exclusive rights to LGC to commercialise and sub-license the technology in September 2001.

Dr Paul Debenham, Director of Life Sciences at LGC, and who has found himself to have the poor metaboliser gene status, said: "There is tremendous excitement in the field of genetically pre-determined drug metabolism, known as pharmacogenetics, about the growing understanding of how each individual may differ in their ability to respond to various medications, and in particular to avoid serious adverse reactions. This is an exciting start to the expansion of the opportunity for the public at large to benefit from understanding their own capability to respond to prescribed medications."


The first sub-licensee, Orchid BioSciences Inc, has taken a non-exclusive licence for North America for an undisclosed sum, and the gene diagnostic will be an essential element in their Orchid GeneShield business focused on pharmacogenomics and personalised medicine. Product offerings being developed by the Orchid GeneShield business are designed to enable physicians, patients and health care providers to better match the right drug to the right patient. LGC is also in discussions with other companies to respond to their interests in licensing and developing tests built around the *4 genetic test.

Dr Richard Worswick, LGC`s Chief Executive, said: "We foresee this as the first of many licensing deals and the forerunner of tremendous growth in the pharmacogenetics business sector. We are most pleased to have completed this non-exclusive agreement with Orchid BioSciences for North America."

Imelda Topping | alfa
Further information:
http://www.lgc.co.uk/news_story.asp?strareano=47_2&intelement=4234

More articles from Health and Medicine:

nachricht A whole-body approach to understanding chemosensory cells
13.12.2017 | Tokyo Institute of Technology

nachricht Research reveals how diabetes in pregnancy affects baby's heart
13.12.2017 | University of California - Los Angeles Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

A whole-body approach to understanding chemosensory cells

13.12.2017 | Health and Medicine

Water without windows: Capturing water vapor inside an electron microscope

13.12.2017 | Physics and Astronomy

Cellular Self-Digestion Process Triggers Autoimmune Disease

13.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>